Login
Companies $PLX
$3.03 +$0.00 (0.0%) After hours
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc.

protalix.com

What Do They Do?

Sells enzyme-replacement therapies for Gaucher and Fabry diseases to pharmaceutical partners, and develops drug candidates for rare diseases.

How Do They Make Money?

Product sales are the main source: customers pay for finished drug products on delivery, with payment terms generally 45 days or less. License and R&D arrangements also bring upfront payments, development-cost reimbursements and milestones.

revenue
SegmentShareRevenue
GOODS
Sold outright

98%
FY2022: 53%
LICENSE AND R&D SERVICES
1.8%
FY2022: 47%

Who Are Their Customers?

Pfizer and Fiocruz buy Elelyso directly, while Chiesi buys Elfabrio and handles its global commercialization and distribution; Protalix retains Elelyso distribution rights in Brazil.

Do Revenues Turn Into Profits?

No. It lost $6.6M in FY2025.

Operating income, FY2025
−10% of revenue
▼ Turned to a loss vs FY2024 ($3.9M, 7%)
Net income, FY2025
−13% of revenue
▼ Turned to a loss vs FY2024 ($2.9M, 5%)
Free cash flow, FY2025
−26% of revenue
▼ Turned to a loss vs FY2024 ($7.4M, 14%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +23%
vs $17.9M in Q3 FY2025
Net income
▲ +68%
vs $2.4M in Q3 FY2025
GOODS share of revenue vs 99.0% in Q3 FY2025
  • Nov 10, 2026 Reaffirmed full-year revenue guidance Management expects total revenue of approximately $78.0 million to $83.0 million, including a $25.0 million Chiesi milestone.

Growing. Revenue grew 38% in 4 years, from $38.4M in FY2021 to $52.7M in FY2025, about 8% a year.

Fabry product enters commercialization The older report described the Fabry treatment as a late-stage candidate awaiting regulatory decisions. The latest report describes it as an approved commercial product.

Broader development approaches The older report emphasized genetically engineering or chemically modifying recombinant proteins, primarily through ProCellEx. The latest report also describes small molecules, antibodies and exploration of other platform technologies.

Revenue over time
GOODS LICENSE AND R&D SERVICES
$100M$50M$0

Who Do They Compete With?

Competes with Sanofi Genzyme, Takeda, Actelion, Amicus, Sangamo Therapeutics, Amgen, Swedish Orphan Biovitrum, Crucell, Dyadic International, Pfenex, iBio, Medicago, and Eleva Biologics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support